Manifestasi Hepatik sebagai Prediktor Mortalitas COVID-19 pada Anak
DOI:
https://doi.org/10.35790/msj.v6i1.50323Abstract
Abstract: Coronavirus disease-19 (COVID-19) has been associated with hepatic involvement in children, often manifesting as elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels during infection. Some retrospective cohorts and case series have shown various degrees of ALT/AST elevation in with a worse disease’s outcome. Yet, the mechanism was still unknown. This study aimed to determine the association of liver involvement with the outcome of COVID-19 infection in infants and children. This was a prospective and observational study. Subjects were 96 infants and children with confirmed COVID-19 at Prof. Dr. R. D. Kandou Hospital from 1 until 31 January 2022. Patient with pre-existing liver diseases or other infections like malaria and hepatitis, were excluded. The results showed that most respondents were aged between 0 days to 17 years; 75.0% had not any comorbidities. The analysis showed that most subjects with normal ALT levels had a survived outcome (97.5%), while most subjects with abnormal ALT levels had a demise outcome (32.1%). However, about 91.5% of the subjects with normal AST levels had a survived outcome. There was a statistically significant relationship between the elevated of ALT (p=0.006) and of AST (p=0.047) variables with the outcome of infants and children with COVID-19 infection. In conclusion, liver enzyme test is a potential parameter for predicting the mortality of pediatric patients with COVID-19.
Keywords: COVID-19; pediatric patients; transaminase enzymes; mortality predictor
Abstrak: Kasus Coronavirus disease-19 (COVID-19) pada populasi anak sering dikaitkan dengan manifestasi pada hepar, yang ditandai dengan peningkatan enzim alanin aminotransferase (ALT) dan aspartat aminotransferase (AST). Studi-studi observasional maupun laporan kasus sebelumnya telah menghubungkan manifestasi hepar pada infeksi SARS-CoV-2 dengan luaran penyakit yang lebih buruk, namun mekanisme dibalik keterlibatan hepar tersebut belum dapat dipastikan. Penelitian ini bertujuan untuk mengetahui hubungan antara keterlibatan hepar terhadap luaran mortalitas penyakit COVID-19 pada anak. Jenis penelitian ialah prospektif dan observasional. Subyek penelitian ialah 96 bayi dan anak yang terkonfirmasi COVID-19 di RSUP Prof. Dr. R. D. Kandou selang 1-31 Januari 2022. Pasien dengan riwayat penyakit hepar sebelumnya atau memiliki tanda-tanda infeksi akut hepar, seperti malaria dan hepatitis, dieksklusi dari studi ini. Hasil penelitian mendapatkan subjek didominasi anak usia 0-17 tahun; 75% tidak memiliki komorbiditas. Pada kelompok dengan luaran hidup, mayoritas (97,5%) memiliki nilai ALT normal, sebaliknya pada kelompok dengan luaran meninggal, 32,1% memiliki nilai ALT meningkat. Terdapat hubungan bermakna antara peningkatan kadar ALT (p=0,006) dan AST (p=0,047) terhadap luaran penyakit COVID-19. Simpulan penelitian ini ialah kadar enzim transaminase hepar dapat menjadi salah satu parameter dalam memrediksi luaran mortalitas anak yang terkonfirmasi COVID-19.
Kata kunci: COVID-19; pasien anak; enzim transaminase hepar; prediktor mortalitas
References
Zare-Zardini H, Soltaninejad H, Ferdosian F, Hamidieh AA, Memarpoor-Yazdi M. Coronavirus disease 2019 (COVID-19) in children: prevalence, diagnosis, clinical symptoms, and treatment. Int J Gen Med. 2020;13:477–82. Available from: https://doi.org/10.2147/IJGM.S262098
Dewi R, Kaswandani N, Karyanti MR, Setyanto DB, Pudjiadi AH, Hendarto A, et al. Mortality in children with positive SARS-CoV-2 polymerase chain reaction test: lessons learned from a tertiary referral hospital in Indonesia. Int J Infect Dis. 2021;107:78–85. Doi: 10.1016/j.ijid.2021.04.019.
Sayed MA, Abdelhakeem M. Typical and atypical clinical presentation of COVID-19 infection in children in the top of pandemic in EL-Minia Governorate (two center experience). Mediterr J Hematol Infect Dis. 2022;14(1):e2022002. Available from: https://doi.org/10.4084%2FMJHID. 2022.002.
Yun YF, Feng ZY, Zhang JJ. COVID-19 and liver dysfunction in children: current views and new hypotheses. World J Hepatol. 2023;15(3):353–63. Available from: http://dx.doi.org/10.4254/ wjh.v15.i3.353.
Wibowo S, Sari TL, Irawan M. Liver Injury in children with COVID-19: a systematic review. Archives of Pediatric Gastroenterology, Hepatology, and Nutrition (APGHN). 2023;2(1):1–15.
Perez A, Cantor A, Miller J, Kogan-Liberman D, Rudolph B, Margolis KG, et al. Acute liver injury in COVID-19: risk factors in a large pediatric cohort. Hepatology. 2020;72(1 Suppl):258A- 259A.
Luglio M, Tannuri U, de Carvalho WB, de Medeiros Bastos KL, Rodriguez IS, Johnston C, et al. COVID-19 and liver damage: narrative review and proposed clinical protocol for critically ill pediatric patients. Clinics. 2020;75:e2250. Available from: https://doi.org/10.6061%2Fclinics%2F2020%2Fe2250
Perez A, Cantor A, Rudolph B, Miller J, Kogan‐Liberman D, Gao Q, et al. Liver involvement in children with SARS‐COV‐2 infection: two distinct clinical phenotypes caused by the same virus. Liver Int. 2021;41(9):2068–75. Doi: 10.1111/liv.14887.
Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatr. 2020;174(9):868–73. Doi: 10.1001/ jamapediatrics.2020.1948.
Leibel SL, Sun X. COVID-19 in early life: infants and children are affected too. Physiology (Bethesda). 2021;36(6):359–66. Doi: 10.1152/physiol.00022.2021.
Garcia-Vargas L, Addison SS, Nistala R, Kurukulasuriya D, Sowers JR. Gestational diabetes and the offspring: implications in the development of the cardiorenal metabolic syndrome in offspring. Cardiorenal Medicine. 2012;2(2):134–42. Doi: 10.1159/000337734.
Lazova S, Alexandrova T, Gorelyova-Stefanova N, Atanasov K, Tzotcheva I, Velikova T. Liver Involvement in children with COVID-19 and multisystem inflammatory syndrome: a single-center Bulgarian observational study. Microorganisms. 2021;9(9):1958. Doi: 10.3390/microorganisms 9091958.
Di Giorgio A, Hartleif S, Warner S, Kelly D. COVID-19 in children with liver disease. Front Pediatr. 2021;9:616381. Available from: https://doi.org/10.3389/fped.2021.616381
Di Sessa A, Lanzaro F, Zarrilli S, Picone V, Guarino S, Miraglia del Giudice E, et al. COVID-19 and pediatric fatty liver disease: is there interplay? World J Gastroenterol. 2021;27(22):3064–72. Doi: 10.3748/wjg.v27.i22.3064.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Suryadi N.N Tatura, Meliana Sulistio
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
